BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20406620)

  • 1. Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells.
    Hong W; Chen L; Li J; Yao Z
    Biochem Biophys Res Commun; 2010 May; 396(2):299-303. PubMed ID: 20406620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
    Fan P; Wang J; Santen RJ; Yue W
    Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen induces the expression of maspin through estrogen receptor-alpha.
    Liu Z; Shi HY; Nawaz Z; Zhang M
    Cancer Lett; 2004 Jun; 209(1):55-65. PubMed ID: 15145521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
    Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
    Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
    Keeton EK; Brown M
    Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.
    Kurokawa H; Lenferink AE; Simpson JF; Pisacane PI; Sliwkowski MX; Forbes JT; Arteaga CL
    Cancer Res; 2000 Oct; 60(20):5887-94. PubMed ID: 11059787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
    Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
    Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
    Bayliss J; Hilger A; Vishnu P; Diehl K; El-Ashry D
    Clin Cancer Res; 2007 Dec; 13(23):7029-36. PubMed ID: 18056179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel ER-alpha target genes in breast cancer cells: gene- and cell-selective co-regulator recruitment at target promoters determines the response to 17beta-estradiol and tamoxifen.
    Romano A; Adriaens M; Kuenen S; Delvoux B; Dunselman G; Evelo C; Groothuis P
    Mol Cell Endocrinol; 2010 Jan; 314(1):90-100. PubMed ID: 19698761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of p21WAF1 expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells.
    Lee TH; Chuang LY; Hung WC
    Oncogene; 2000 Aug; 19(33):3766-73. PubMed ID: 10949931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells.
    Kronblad A; Hedenfalk I; Nilsson E; Påhlman S; Landberg G
    Oncogene; 2005 Oct; 24(45):6835-41. PubMed ID: 16007158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
    J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
    Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
    Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity.
    Peterson TJ; Karmakar S; Pace MC; Gao T; Smith CL
    Mol Cell Biol; 2007 Sep; 27(17):5933-48. PubMed ID: 17591692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
    Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
    Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by Early Growth Response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells.
    Kim CG; Choi BH; Son SW; Yi SJ; Shin SY; Lee YH
    Cell Signal; 2007 Jun; 19(6):1290-300. PubMed ID: 17307334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.